Unfortunately at the moment they still come across as a group who have found or created some interesting technology, but their expertise seems to be in the peptide and cpp side of things, rather than in the medical side. As such they know their stuff with cpp but are constantly stunned or stymied when they try to apply that technology to any medical application, as they seem to struggle without external assistance. At least the recent trials with cancer were a sign they are using experts in the field now to try and develop their tech. I guess it goes to show why a deal of some kind with a development company would be so good. Trouble is cpp appears to be so far from market no one is going to collaborate and pay us heaps. Any deal would suck more funds in the hope we find a golden bullet. Interesting year coming up (again lol)
Would be nice to see some of the durectors swap out and be replaced by a cancer expert of some description if that is where we are heading.
PYC Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)